Bruker Reports Third Quarter 2026 Financial Results
Business Wire•04/11/2026•07:00 ET
0
Key Highlights
- ➤Q3-26 revenue $874.0 million, up 1.6% yoy
- ➤Q3-26 non-GAAP diluted EPS $0.56, up 24.4% yoy
- ➤Q3-26 non-GAAP operating margin 16.3%, up 400 bps yoy
- ➤$174.5 million goodwill impairment drove Q3-26 GAAP operating loss $(91.0) million
- ➤FY26 revenue and non-GAAP EPS guidance reaffirmed at $3.52-$3.56 billion and $2.10-$2.15
Expert Statements
Frank H. Laukien, President and CEO of Bruker Corporation
“Bruker drives significant advances in post-genomic drug discovery and disease biology research, from proteoforms to glycobiology, and from functional protein interactions to spatial biology. These deeper insights into molecular, cell and tissue biology are foundational for successful drug development and useful AI frontier models. Together with strong growth-drivers in infectious disease diagnostics, and in deep-tech and semiconductor metrology, we are poised for growth acceleration.”
Frank H. Laukien, President and CEO of Bruker Corporation
“In the third quarter, we achieved very significant margin expansion and non-GAAP EPS growth, driven by our focus on cost discipline and execution. Bruker’s positive booking trends continued with the fifth consecutive quarter of Bruker Scientific Instruments (BSI) book-to-bill greater than one. We see strengthening demand in most of our end markets, and in Q3 also in the US academic market. With BSI organic bookings and backlog both up mid-single digits % year-to-date, we expect revenue growth acceleration, continued margin expansion and double-digit EPS growth in FY27.”
Q3-26 revenue of $874.0 million, up 1.6% yoy; up 0.7% organically
* Q3-26 GAAP diluted Loss Per Share of $(0.81); Non-GAAP diluted EPS of $0.56, up 24.4% yoy
Get started
Create a free account to read the full story.